(1-甲基-1H-咪唑-2-基)甲胺盐酸盐 | 161493-94-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: (1-甲基-1H-咪唑-2-基)甲胺盐酸盐
• 中文别名: 1-(1-甲基-1H-咪唑-2-基)甲胺盐酸盐
• 英文名称: C-(1-methyl-1H-imidazol-2-yl)-methylamine dihydrochloride
• 英文别名: (1-Methyl-1H-imidazol-2-yl)methanamine hydrochloride；(1-methylimidazol-2-yl)methanamine;hydrochloride
• CAS: 161493-94-3
• 化学式: C₅H₉N₃*2ClH
• 分子量: 184.068
• InChiKey: TZBZZSKMXFFYGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  43.8
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  (1-甲基-1H-咪唑-2-基)甲胺盐酸盐 、 (R/S)-2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetic acid 在 N-甲基吗啉 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以13%的产率得到(R/S)-2-hydroxy-N-((1-methyl-1H-imidazol-2-yl)methyl)-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetamide
  参考文献：
  名称：

  [EN] 4 - (5 - ISOXAZOLYL OR 5 - PYRRAZOLYL -1,2,4- OXADIAZOL - 3 - YL) -MANDELIC ACID AMIDES AS SPHINGOSIN- 1 - PHOSPHATE 1 RRECEPTOR AGONISTS
  [FR] AMIDES D'ACIDE 4-(5-ISOXAZOLYL OU 5-PYRAZOLYL-1,2,4-OXADIAZOL-3-YL)-MANDÉLIQUE COMME AGONISTES DU RÉCEPTEUR DE LA SPHINGOSINE-1-PHOSPHATE DE TYPE 1

  摘要：

  揭示了Formula (I)的化合物或其立体异构体、盐或前药，其中：Q是，或者R1是苯基，其上取代基为零至3个；而R1、R2、R3、R4、R5和G在此处有定义。还揭示了将这些化合物用作G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或紊乱方面具有用处，如自身免疫疾病和血管疾病。

  公开号：

  WO2011133734A1

文献信息

• [EN] 2-(1H-INDAZOL-6-YLAMINO)-BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTALMIC DISEASES<br/>[FR] COMPOSES DE 2-(1H-INDAZOL-6-YLAMINO)-BENZAMIDES EN TANT QU'INHIBITEURS DE PROTEINES KINASES UTILES POUR LE TRAITEMENT DE MALADIES OPHTALMIQUES
  申请人：PFIZER

  公开号：WO2004056806A1

  公开（公告）日：2004-07-08

  Indazole compounds that modulate and/or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating ophthalmic diseases and cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma,rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  描述了可以调节和/或抑制眼科疾病和某些蛋白激酶活性的吲哚唑化合物。这些化合物和含有它们的药物组合物能够介导酪氨酸激酶信号传导，从而调节和/或抑制不需要的细胞增殖。该发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效剂量来治疗眼科疾病和癌症以及与不需要的血管生成和/或细胞增殖相关的其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣。
• Scalable Synthesis of Piperazines Enabled by Visible-Light Irradiation and Aluminum Organometallics
  作者：Samuel Suárez-Pantiga、Kilian Colas、Magnus J. Johansson、Abraham Mendoza

  DOI：10.1002/anie.201505608

  日期：2015.11.16

  The development of more active CH oxidation catalysts has inspired a rapid, scalable, and stereoselective assembly of multifunctional piperazines through a [3+3] coupling of azomethine ylides. A combination of visible‐light irradiation and aluminum organometallics is essential to promote this transformation, which introduces visible‐light photochemistry of main‐group organometallics and sets the basis

  更活性的C - H氧化催化剂的开发激发了通过偶氮甲碱叶立德的[3+3]偶联来快速、可规模化和立体选择性地组装多功能哌嗪。可见光照射和铝有机金属的结合对于促进这种转变至关重要，它引入了主族有机金属的可见光光化学，并为新型有前途的催化剂奠定了基础。
• Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US20040192735A1

  公开（公告）日：2004-09-30

  Indazole compounds that modulate and/or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating ophthalmic diseases and cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  本文描述了调节和/或抑制眼科疾病和某些蛋白激酶活性的吲唑化合物。这些化合物和含有它们的药物组合物能够介导酪氨酸激酶信号传导，从而调节和/或抑制不必要的细胞增殖。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效量来治疗眼科疾病和与不必要的血管生成和/或细胞增殖相关的癌症和其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和银屑病。
• MANDELAMIDE HETEROCYCLIC COMPOUNDS
  申请人：Cherney Robert J.

  公开号：US20130045964A1

  公开（公告）日：2013-02-21

  Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: Q is, or R 1 is phenyl substituted with zero to 3 substituents; and R 1 , R 2 , R 3 , R 4 , R 5 , and G are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及式（I）的化合物或其立体异构体、盐或前药，其中：Q是，或R1是带有零到3个取代基的苯基；R1、R2、R3、R4、R5和G在此处被定义。还公开了使用这些化合物作为选择性G蛋白偶联受体S1P1的激动剂的方法，以及包含这些化合物的制药组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病的进展中有用，例如自身免疫性疾病和血管疾病。
• Pharmaceutical composition containing quinoline or quinazoline derivatives
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0634169A1

  公开（公告）日：1995-01-18

  The present invention provides a pharmaceutical composition for inhibiting bone resorption or for preventing or treating osteoporosis which comprises a quinoline or quinazoine derivative as an active ingredient.

  本发明提供了一种用于抑制骨吸收或预防或治疗骨质疏松症的药物组合物，其活性成分包括喹啉或喹唑啉衍生物。